Immunovaccine to Host Annual General Meeting

HALIFAX, NOVA SCOTIA -- (Marketwire) -- 05/22/12 -- Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE: IMV), a clinical stage vaccine company developing the patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy and infectious diseases, today announced that it will host its Annual General Meeting (AGM) of shareholders on Thursday, May 24, 2012. The AGM will be held at 12:30 p.m. AST at the Company's headquarters located at 1344 Summer Street, Halifax, Nova Scotia.

Additionally, Immunovaccine will broadcast the AGM live via webcast. The webcast can be accessed by visiting: A link to the webcast will also be available on the Investors page of the Immunovaccine website ( Following the live broadcast, an archive of the webcast will be available on Immunovaccine's website for 90 days.

Individuals can also access an audio version of the AGM broadcast by phone using the following details:

Dial In Number:      866-240-8955
Confirmation Number: 4133389
Company Name:        Immunovaccine Inc.
Moderator Name:      John Trizzino

About Immunovaccine

Immunovaccine Inc. applies its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious disease. The company's DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I human trials and has demonstrated both safety and immunogenicity potential. The company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. The company has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the company's delivery technology platform to develop vaccines for livestock. Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Immunovaccine Inc.
Kimberly Stephens
(902) 492-1819

Vida Communication (media)
Tim Brons
(415) 675-7402

Vida Communication (investors)
Stephanie Diaz
(415) 675-7401

Source: Immunovaccine Inc.